Sanofi(SNY)Earnings, Financials & Key RatiosSanofi (SNY) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2025Q4
while the 5.9% dividend yield and low 10.20 forward P/E ratio offer value, the extreme volatility in quarterly net income and cash flow conversion suggests that investors should wait for more consistent operational performance before increasing exposure.
Sanofi (SNY) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Sanofi (SNY) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 23, 2026 | $1.10vs $1.06+3.8% | $12.9Bvs $12.7B+2.1% |
| Q1 2026 | Jan 29, 2026 | $0.89vs $0.84+6.0% | $14.3Bvs $11.7B+22.4% |
| Q4 2025 | Oct 24, 2025 | $1.70vs $1.60+6.3% | $15.4Bvs $11.1B+38.9% |
| Q3 2025 | Jul 31, 2025 | $0.90vs $0.96-6.3% | $12.6Bvs $12.4B+2.3% |
Recent stock market news and headlines for Sanofi (SNY)
Sanofi's phase III Baby-COMET study meets all goals for Nexviazyme in infantile-onset Pompe disease, paving the way for a planned U.S. filing in H2 2026.
Availability of the aide-mémoire for Q2 2026 results Paris, France – July 1, 2026. Sanofi announced today the availability of the aide-mémoire for Q2 2026 results on the "Investors" page of sanofi.com: Second quarter 2026 results Prepared each quarter, this document is intended to support financial modelling of the quarterly results.
When dividend stocks drop in value, investors have the opportunity to secure some higher-than-typical yields. The stocks listed here haven't been doing well this year, but they offer some attractive dividend income.
Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?
The European Commission opened on Friday an investigation into whether French drug giant Sanofi breached EU competition rules in a flu vaccine marketing campaign.
Key metrics vs top competitors for Sanofi (SNY)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $42.98 | $103.34B | 11.75 | 5.49% | 16.72% | 10.45% | 5.87% | |
| $49.64 | $220.59B | 14.10 | 6.43% | 37.2% | 66.36% | — | |
| $193.12 | $299.39B | 29.53 | 8.63% | 17.19% | 22.24% | — | |
| $157.03 | $299.63B | 21.84 | 5.97% | 24.14% | 31.42% | — | |
| $53.32 | $107.23B | 7.16 | 4.11% | 19.19% | 31.48% | — | |
| $24.07 | $136.92B | 17.70 | -1.65% | 11.83% | 8.34% | — |
Sanofi (SNY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when SNY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Sanofi (SNY) stock FAQ — growth, dividends, profitability & financials explained
Sanofi (SNY) reported $46.72B in revenue for fiscal year 2025. This represents a 773% increase from $5.35B in 1999.
Sanofi (SNY) grew revenue by 5.5% over the past year. This is steady growth.
Yes, Sanofi (SNY) is profitable, generating $7.81B in net income for fiscal year 2025 (16.7% net margin).
Yes, Sanofi (SNY) pays a dividend with a yield of 5.87%. This makes it attractive for income-focused investors.
Sanofi (SNY) has a return on equity (ROE) of 10.4%. This is reasonable for most industries.
Sanofi (SNY) generated $8.28B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
